Clinical Trial Update: A Study of YTS109 Cell in Subjects With Relapsed/Refractory Autoimmune Hemolytic Anemia [Phase 1]

View source ↗

Summary

Phase 1 trial update for YTS109 cell therapy in relapsed/refractory autoimmune hemolytic anemia; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autoimmune Hemolytic Anemia

Drugs mentioned

• YTS109

Snippet

Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Conditions: Autoimmune Hemolytic Anemia | Phase 1 | Status: NOT_YET_RECRUITING